Mattias Ivarsson is committed to fighting a nasty bacterium at the root of many hospital-acquired infections. This article describes the story behind Inositec’s technology and CEO.
10th November 2014
Categories
Most Recent
- Interview of Inositec CEO by Scrip Intelligence
- Inositec AG Secures CHF1.4 million in Seed Financing to Advance New Class of Inositol Hexaphosphate-Based Drug Candidates
- Inositec nominated for the 2016 deVigier prize
- Inositec CEO named on Forbes 30 under 30 list
- Inositec CEO featured in ETH Globe magazine